中成藥香港註冊要求與遞交資料

What Are the Registration Requirements for Proprietary Chinese Medicines in Hong Kong?

Proprietary Chinese medicines (pCm) sold or manufactured in Hong Kong must be registered with the Chinese Medicine Council of Hong Kong (CMCHK) under the Chinese Medicine Ordinance (Cap. 549). The registration framework, administered by the Chinese Medicines Board, aims to ensure the safety, quality and efficacy of pCm products available to the public. The key deadline for the industry is 2026-06-5, by which all pCm products must have obtained registration or a transitional approval to remain on the market. This article outlines the core registration requirements, the documentation needed for an application, and the practical steps to achieve compliance before the deadline.

Who Must Register?

Any person or company intending to manufacture, import, sell or supply a proprietary Chinese medicine in Hong Kong must apply for registration. This includes local manufacturers, importers, wholesalers and retailers. The obligation rests with the “responsible person” – typically the manufacturer or the importer – who must ensure the product meets all regulatory standards.

What Is a Proprietary Chinese Medicine?

Under the Ordinance, a proprietary Chinese medicine is any Chinese medicine product that is formulated in a finished dose form and sold under a specific brand name. It excludes raw herbs or simple preparations dispensed by a Chinese medicine practitioner for an individual patient. Examples include pills, capsules, granules, ointments and oral liquids that are pre-packaged and labelled for retail sale.

Key Regulatory References

The primary legislation is the Chinese Medicine Ordinance (Cap. 549), supplemented by guidelines issued by the CMCHK. The Chinese Medicine Council of Hong Kong – pCm Registration portal provides the official application forms, guidance notes and the list of required documents. The Department of Health’s Chinese Medicines Division also oversees licensing of Chinese medicine traders, which is a separate but related requirement for businesses handling pCm.

Who Should Consider Chinese Medicine Registration and Key Planning Decisions

Any person or company intending to manufacture, import, distribute, or sell a proprietary Chinese medicine (pCm) in Hong Kong must carefully consider the registration requirements under the Chinese Medicine Ordinance (Cap. 549). This includes local manufacturers, overseas producers seeking market access, wholesalers, retailers, and even healthcare practitioners who dispense their own formulated products. According to the Chinese Medicine Council of Hong Kong, the registration framework applies to any pCm that is sold or supplied in Hong Kong, unless specifically exempted. Early planning is essential, as the registration process involves multiple stages and requires detailed documentation on safety, quality, and efficacy.

Key planning decisions revolve around product classification, the appropriate registration category, and the assembly of a compliant technical dossier. Applicants must determine whether their product falls under the “Classical formula,” “New formula,” or “Generic” category, as each has distinct evidentiary requirements. For instance, classical formulas may rely on authoritative pharmacopoeia references, while new formulas typically require comprehensive safety and efficacy data. Additionally, the choice of a Hong Kong-based responsible person or agent is critical for overseas applicants, as this entity will liaise with the regulatory authorities and maintain local records. Engaging professional advisors early can help navigate these decisions and avoid costly delays.

Preparing for Chinese Medicine Registration in Hong Kong: Key Information to Gather

Before initiating the registration process for proprietary Chinese medicines (pCm) in Hong Kong, applicants must assemble a comprehensive dossier that aligns with the requirements of the Chinese Medicine Council of Hong Kong (CMCHK) under the Chinese Medicine Ordinance (Cap. 549). The preparation stage is critical, as incomplete submissions are a common cause of delay. The CMCHK’s proprietary Chinese medicine registration portal outlines the necessary documentation, which includes detailed product information, evidence of safety, quality and efficacy, and proof of compliance with Good Manufacturing Practice (GMP) standards. Applicants should first confirm the classification of their product—whether it falls under the definition of a proprietary Chinese medicine—and identify the appropriate registration category (e.g., new medicine, generic medicine, or a product already on the market before the Ordinance came into effect). Gathering information on the product’s formulation, active ingredients, therapeutic claims, and manufacturing process is essential. Additionally, the applicant must be a holder of a valid wholesale dealer licence for Chinese medicines issued by the Chinese Medicines Board, as referenced in the Chinese Medicine Traders licensing page. Early engagement with a qualified consultant or the Department of Health’s Chinese Medicine Division can help clarify the specific data requirements for the intended registration pathway, ensuring a smoother submission process.

Step-by-Step Application Process for Chinese Medicine Registration in Hong Kong

Navigating the registration process for proprietary Chinese medicines (pCm) in Hong Kong requires careful preparation and adherence to the framework established under the Chinese Medicine Ordinance (Cap. 549). The Chinese Medicine Council of Hong Kong (CMCHK) oversees the registration, and the application is submitted through the Chinese Medicines Section of the Department of Health. Below is a structured overview of the key steps, based on the official guidelines available on the CMCHK website.

1. Determine the Registration Category

Before applying, identify which of the three registration categories applies to your product: “new medicine,” “generic medicine,” or “classical formula.” The category dictates the type and extent of supporting data required. For instance, a new medicine demands comprehensive safety and efficacy data, while a classical formula may rely on documented traditional use. This classification is fundamental to assembling the correct dossier.

2. Prepare the Application Dossier

The core of the submission is a detailed dossier that must include administrative information, product specifications, and technical data. According to the CMCHK, the dossier typically covers:

• Administrative documents: Completed application form, business registration certificate of the applicant, and a letter of authorization if the applicant is not the manufacturer.
• Product information: Proposed product name, dosage form, packaging specifications, and full ingredient list with quantities.
• Quality control: Evidence of Good Manufacturing Practice (GMP) compliance, stability testing data, and quality standards for each ingredient and the finished product.
• Safety and efficacy: Depending on the category, this may include toxicological studies, clinical trial reports, or bibliographic evidence of traditional use.

3. Submit the Application

Applications are submitted to the Chinese Medicines Section of the Department of Health. The submission must be accompanied by the prescribed fee. Upon receipt, the authority conducts a preliminary screening to ensure all required documents are included. Incomplete submissions are returned, which can delay the process.

4. Technical Evaluation

Once accepted, the application undergoes a thorough evaluation by the relevant committees under the CMCHK. This includes assessment of the product’s quality, safety, and efficacy. The evaluation may involve requests for additional information or clarification from the applicant. The timeline for this stage varies depending on the complexity of the product and the completeness of the initial submission.

5. Issuance of Registration Certificate

If the evaluation is satisfactory, the CMCHK issues a certificate of registration. The registration number must be displayed on the product label. The registration is subject to conditions, including adherence to GMP and ongoing pharmacovigilance obligations. Note that the registration is not a one-time event; it may require renewal or variation if there are changes to the product.

For the most current and detailed guidance, applicants should refer directly to the Chinese Medicine Council of Hong Kong’s official resources on pCm registration.

Key Documents and Evidence Required for Chinese Medicine Registration in Hong Kong

Applicants must prepare a comprehensive dossier that substantiates the safety, quality and efficacy of the proprietary Chinese medicine. The following checklist outlines the core submissions required under the Chinese Medicine Ordinance (Cap. 549) and the guidelines of the Chinese Medicine Council of Hong Kong.

Product Identity and Formulation

Submit the full product name, dosage form, a complete list of active ingredients with their quantities, and a description of the container and packaging. This establishes the product’s unique identity and ensures traceability of every component.

Manufacturing Information

Provide the name and address of the manufacturer, a copy of the manufacturer’s licence or GMP certificate, and a detailed description of the manufacturing process. This demonstrates that the product is consistently produced under controlled conditions that meet Hong Kong’s standards.

Safety and Stability Data

Include reports of heavy metal and toxic element testing, microbial limit tests, and stability studies. These data are critical to confirm that the product remains safe and retains its quality throughout its shelf life under recommended storage conditions.

Efficacy and Usage Evidence

Supply pharmacological and clinical study reports, or references to traditional literature, to support the claimed therapeutic actions. Clear indications, dosage instructions, contraindications and possible adverse effects must be stated to guide safe use.

Labelling and Package Insert

Submit a mock-up of the product label and package insert in both Chinese and English, showing all mandatory information such as the registration number, batch number, expiry date and storage conditions. This ensures compliance with the labelling requirements under Cap. 549.

Preparing and Submitting the Application Dossier for Chinese Medicine Registration in Hong Kong

Once the applicant has determined the appropriate registration category and confirmed the product’s eligibility under the Chinese Medicine Ordinance (Cap. 549), the focus shifts to compiling a comprehensive application dossier. The Hong Kong Chinese Medicine Board requires a structured set of documents that demonstrate the product’s safety, quality, and efficacy. While the exact list varies by category, a typical submission includes a completed application form, proof of the applicant’s legal status (such as a valid business registration certificate), and detailed product information. This encompasses the proprietary name, dosage form, a full list of active ingredients with their quantities, and a description of the manufacturing process. For products classified as proprietary Chinese medicines, the Board also expects evidence of Good Manufacturing Practice (GMP) compliance from the manufacturer, which is a critical factor in the assessment of product quality.

Key Documents and Data Requirements

Applicants must provide stability testing data to support the proposed shelf life, along with specifications for the finished product and any relevant test methods. If the product has a history of use in other jurisdictions, submission of foreign registration certificates or free sale certificates can be helpful, though they do not replace the need for local evaluation. For products making therapeutic claims, the dossier should include clinical trial data or published literature that substantiates those claims according to the standards referenced by the Chinese Medicine Council of Hong Kong. It is essential to ensure that all documents are in either Chinese or English, or accompanied by a certified translation. The Board may request additional information or samples during the review process, and failure to respond in a timely manner can lead to delays or refusal of the application. Engaging a professional service provider familiar with the submission portal and documentation nuances can help avoid common pitfalls and streamline the path toward obtaining a registration number for the Chinese medicine product.

Common Mistakes, Risk Controls, and Practical Next Steps for Chinese Medicine Registration in Hong Kong

When preparing a Chinese medicine product registration under the Chinese Medicine Council of Hong Kong, applicants frequently encounter avoidable setbacks. A recurring mistake is submitting incomplete or inconsistent documentation, particularly where the product formula does not precisely match the manufacturing records or the label claims. Under the Chinese Medicine Ordinance (Cap. 549), the Council may reject applications that lack a clear traceability between the raw herbs, the extraction process, and the finished product specification.

Risk Controls to Strengthen Your Application

To mitigate the risk of refusal, establish a robust internal review process before submission. Verify that the proposed product name does not imply exaggerated therapeutic effects, as this can trigger a request for additional clinical evidence. Ensure that the manufacturer holds a valid Chinese medicines trader licence (wholesale) where applicable, and that the responsible person designated in the application meets the qualification requirements set by the Council. Cross-reference all submitted data with the official guidance on the Council’s website, and consider engaging a professional service familiar with the evolving regulatory expectations.

Practical Next Steps After Submission

Once the application is lodged, monitor the status through the Council’s communication channels and respond promptly to any queries. Keep a complete dossier of all correspondence and supplementary submissions, as these may be requested during post-registration surveillance. If the product formulation or labelling changes during the review period, proactively inform the Council to avoid delays. For businesses aiming to meet the 中成藥香港註冊 2026-06-5 timeline, early preparation and meticulous attention to the documentary requirements are essential to navigate the registration pathway efficiently.

Closing Remarks and Practical Next Steps

Navigating the registration of proprietary Chinese medicines in Hong Kong under the Chinese Medicine Ordinance (Cap. 549) requires careful preparation of technical dossiers, adherence to Good Manufacturing Practice (GMP) standards, and clear demonstration of safety, quality and efficacy. While the process may appear demanding, early engagement with the Chinese Medicine Council of Hong Kong and its subsidiary boards can help clarify expectations and avoid common pitfalls. Applicants are encouraged to consult the official guidelines published by the Chinese Medicines Board and to consider professional support for dossier compilation, particularly for products with complex formulations or limited historical use data. Staying informed of any transitional provisions and deadline extensions remains essential for maintaining market access.

Frequently Asked Questions

Preparing for the 2026-06-5 Deadline: Practical Steps for Applicants

With the transitional registration period set to conclude on 2026-06-5, holders of existing transitional registration certificates must now focus on converting to full registration. This process requires a thorough review of previously submitted data and the preparation of additional evidence to meet the more stringent standards for full registration. The Chinese Medicine Council of Hong Kong, through the Chinese Medicines Board, has outlined specific documentary requirements that vary depending on the product category—whether it is a proprietary Chinese medicine with a known formula, a classical formula, or a new formula. Applicants should first confirm the correct classification of their product, as this determines the type and extent of safety, quality, and efficacy data required.

Assembling the Required Documentation

For most products, the core submission package includes a completed application form, proof of business registration, a manufacturing licence or GMP certificate, detailed product specifications, stability test reports, and, where applicable, clinical trial data or literature-based evidence of safety and efficacy. The Chinese Medicine Ordinance (Cap. 549) and its subsidiary regulations provide the legal framework, and the Chinese Medicine Council of Hong Kong publishes detailed guidance notes on its website. It is crucial to ensure that all documents are in the prescribed format and, if originally in a language other than Chinese or English, accompanied by certified translations. Missing or incomplete documentation is a common reason for processing delays or rejection.

Engaging Professional Assistance

Given the complexity of the registration process, many applicants choose to engage a consultant or a registered Chinese medicine practitioner experienced in regulatory affairs. These professionals can help interpret the requirements, prepare the necessary technical dossiers, and communicate with the Chinese Medicines Board on the applicant’s behalf. While not mandatory, such support can significantly reduce the risk of errors and expedite the review process. As the deadline approaches, early preparation and professional guidance are key to ensuring a smooth transition to full registration under the Chinese Medicine Ordinance.